PharmaCore
High Point
About PharmaCore
PharmaCore is a leading partner in small molecule drug discovery, development and manufacturing for pharmaceutical and biotechnology companies. The PharmaCore offering parallels the drug discovery process and provides significant advantages at each step from lead discovery to lead optimization, chemical synthesis and scale-up of pharmaceutical intermediates as well as chemical process R&D. PharmaCore is an industry leader in custom organic synthesis using diverse chemistries to produce active pharmaceutical ingredients and scaffolds. PharmaCore has GMP manufacturing facilities for scale-up of pharmaceutical APIs in gram to multi-kilogram quantities. These facilities include eight GMP production areas with reactors to 2000 liters. In support of our GMP manufacturing, PharmaCore’s experienced Quality Assurance department assures compliance with current FDA and international regulations. At PharmaCore, we are equipped to provide non GMP and GMP API manufacture from grams to 100’s of kilograms. PharmaCore has a state-of-the-art cGMP analytical services laboratories. Offering a diverse range of analytical testing capabilities and experienced methods development and validation services, as well as years of industry-proven expertise, PharmaCore can meet your analytical needs, big or small, long-range or short. At PharmaCore we are licensed to manufacture controlled substances in schedules 2-5. We have experience in the logistics management of these regulated materials under licenses that include Analytical, Research and Manufacturing. Many of our clients utilize PharmaCore’s highly experienced scientists as an extension of their own chemistry team by way of short and long term contract research programs.
Company Facts
- Operating status: Closed
- Company type: For Profit
- IPO status: Private
- Employees: 101 – 250
- Estimated revenue: $10K – $50K
- Website: pharmacore.com
- Phone: (336)841-5250
Social Profiles
Canonical: https://fsome.com/organization/pharmacore-3038656 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.